Of clinical significance, firstly, numerous experimental and approved clinical medicines targeting specific receptors (such as MC4R, GLP1R and LepR) are currently being targeted to treat obesity.62–65 In this respect, it would be worthwhile to utilize the newly identified receptor GRM3 for further anti-obesity drug discovery. Here, GRM3 is linked to obesity due to melanocortin 4 receptor deficiency.